Blue Water Ventures International, Inc. · OTC:BWVI
Blue Water Ventures International — Psycheceutical Bioscience — Investor Presentation (January 2023)
27 slides from Blue Water Ventures International's investor presentation, January 2023
Slide 1: Investor Presentation
STATE-OF-THE-ART PSYCHEDELIC DELIVERY TECHNOLOGIES INVESTOR PRESENTATION JANUARY 2023
Slide 2: Disclaimers
DISCLAIMERS This presentation of Psycheceutical Bioscience, Inc., together with its wholly owned subsidiary Psycheceutical, Inc. (the “Company” or global economy; the Company’s ability to implement its strategy or operate its business as the Company currently expects; the “Psycheceutical”), is for i
Slide 3: Our Vision
OUR VISION Using patented, cutting-edge delivery technologies to provide safe and effective bioavailable psychedelic pharmaceutical medicines. Investor Presentation | Jan. 2023 | 3
Slide 4: Background
BACKGROUND Our mission at Psycheceutical is to develop, improve, and commercialize cutting-edge delivery technologies that can Psycheceutical is a biopharmaceutical company that is be used across the mental health treatment spectrum fundamentally changing the deployment of psychedelics while providi
Slide 5: The Problem
THE PROBLEM Unsafe Dosing Prevents Widespread Use of Lifesaving Psychedelics Lower bioavailability results in fewer Higher doses are required to achieve the compounds reaching the targeted site. desired effect, yet over-concentration Most compounds don’t easily cross the blood- leads to adverse reac
Slide 6: The Solution: Psycheceutical Technologies
THE SOLUTION: PSYCHECEUTICAL TECHNOLOGIES Psycheceutical is focused on the development and acquisition of pharmaceutical products and technologies which offer increased safety and efficacy as well as alternative delivery methods for current psychedelic therapies, thereby improving patient outcomes.
Slide 7: Psycheceutical's Non-Systemic Delivery Solution
PSYCHECEUTICAL’S NON-SYSTEMIC DELIVERY SOLUTION Our patented NeuroDirect™ technology is being designed to deliver neuro-active compounds directly into the nerve tissue via topical application at the back of the neck. This delivery system is intended to enable immediate and sustained delivery, safe d
Slide 8: Psycheceutical Novel Delivery Goals
PSYCHECEUTICAL NOVEL DELIVERY GOALS NeuroDirect™ Patented Delivery Technology ! Delivery to introduce neuro-affective agents directly into ! Minimize significant adverse reactions (The NeuroDirect™ nerve tissue, designed to result in much lower dosing and lower dosage delivery has shown symptom redu
Slide 9: Psycheceutical's Systemic Janus Particles Solution
PSYCHECEUTICAL’S SYSTEMIC JANUS PARTICLES SOLUTION Our patented Janus particles manufacturing process, based on recent breakthrough discoveries at the University of Michigan, is being developed to target specific cells and deliver multiple medicines at different times and rates. Key features we have
Slide 10: Patented Janus Particles Manufacturing
PATENTED JANUS PARTICLES MANUFACTURING We believe that our patented manufacturing process will be able to deliver psychedelics and other complementary compounds at scale, in nearly any required size or shape, in a cost-effective and consistent manner. The vision is that our Janus particles will be a
Slide 11: Psycheceutical Janus Particles Goals
PSYCHECEUTICAL JANUS PARTICLES GOALS Janus Particle Patented Manufacturing Technology ! Issued and pending patents provide worldwide exclusivity ! Excellent product stability to provide long shelf life in for manufacturing and sale of products. a wide range of temperature storage conditions. ! Unifo
Slide 12: Compounds & Delivery Methods in Our Focus
COMPOUNDS & DELIVERY METHODS IN OUR FOCUS Molecules We Are Targeting Potential Delivery Methods KETAMINE PSILOCYBIN IBOGAINE ORAL TOPICAL NASAL MDMA DMT LSD TRANSDERMAL RECTAL Investor Presentation | Jan. 2023 | 12
Slide 13: Who We Are
WHO WE ARE FDA Drug Development Veterans Our talented team of industry experts has 100+ years of combined experience in psychedelics, biotechnology, and business development across the pharmaceutical industry. Technology and Mental Health Science Experts Our visionary founders and advisors are consi
Slide 14: Leadership
LEADERSHIP CHAD HARMAN DR. ANISH TUTEJA MICHAEL HLAVSA Chief Executive Officer Chief Science Officer Chief Financial Officer Chad Harman is a 25-year cannabis and health Dr. Anish Tuteja is a Professor of Materials Michael Hlavsa has 44 years of executive and insurance executive possessing unique Sc
Slide 15: Medical Advisory Board
MEDICAL ADVISORY BOARD JULIAN E. BAILES, MD DR. THOMAS CABELL DR. TONY STRICKLAND Chief Medical Officer, Board Member Medical Advisor Medical Advisor Julian E. Bailes, MD is a recognized leader in the Dr. Thomas Cabell is a cardiologist and is Dr. Tony Strickland is a board-certified field of neuros
Slide 16: Science Team
SCIENCE TEAM RONALD AUNG-DIN, MD DR. ANISH DHANARA JAN Clinical Advisor R&D Advisor Dr. Ronald Aung-Din practices General Dr. Anish Dhanarajan has Ph.D. in Biomedical Neurology and Neuro-Psychiatry in Sarasota, Engineering/Chemical Engineering from the Florida. He is board-certified by the American
Slide 17: Brand Awareness Team
BRAND AWARENESS TEAM KEVIN HARRINGTON ZAPPY ZAPOLIN KAIA ROMAN Strategic Advisor Chief Visionary Officer VP of Strategy and Communications Kevin Harrington is an entrepreneur, investor, Zappy Zapolin is a well-known futurist, Kaia brings 20 years of PR and marketing business executive and best-selli
Slide 18: Psycheceutical's Brand Awareness
PSYCHECEUTICAL’S BRAND AWARENESS Featured Articles In: Featured Speakers At: “Shark Tank’s Kevin “Psycheceutical Licenses Harrington Invests in New Delivery Psychedelics Company Technologies For Psycheceutical” Psychedelic Medicines” Wonderland:Miami “Biotech Company “Novel Psychedelic Treatment Ear
Slide 19: Market Potential
MARKET POTENTIAL Over $100 Billion Global Mental Health Market for Psychedelic Medicine DEPRESSION ADHD ADDICTION $15B $13B $42B Global annual Global annual Substance abuse depression drug sales ADHD drug sales treatment market ANXIETY PAIN PTSD $5B $80B $16B Global annual Global annual Global annua
Slide 20: Our Strategy
OUR STRATEGY Our goal is to develop our assets for all targeted areas of commercial use, focusing initially on near-term licensing and strategic partnership opportunities, while exploring on an ongoing basis all avenues for achieving maximum benefit from our assets for the pharmaceutical and drug de
Slide 21: Business Model: Capturing Dual Revenue Streams
BUSINESS MODEL: CAPTURING DUAL REVENUE STREAMS Psycheceutical intends to leverage its novel technology in two highly profitable sectors: licensing technology & drug development. B2B Channel In-House IP and Drug Development It is our intention to license our drug delivery technology We intend to deve
Slide 22: Speed to Market Strategies
SPEED TO MARKET STRATEGIES Technology Co-Development Artificial Intelligence & Machine Learning ! The company will assist in the validation of the Janus Particle The company is in technology partnership discussions with technology with the scale up of manufacturing capabilities Aivance Health on an
Slide 23: Drug Pipeline: Pre-Clinical
DRUG PIPELINE: PRE-CLINICAL NeuroDirectTM Topical for the Treatment of PTSD ! Non-GLP observational data reflects reduction in ! Yearly market opportunity $1B+ symptoms via Hamilton depression scale (FDA gold standard) without side effects ranging from ! Pre-Clinical phase of R&D topical formulation
Slide 24: Drug Pipeline: Pre-Clinical
DRUG PIPELINE: PRE-CLINICAL Administration for the Treatment of Addiction ! Yearly market opportunity $20B+ ! Defendable patent protection ! Pre-Clinical phase ! Company will pursue sales or licensing of the technology during Phase II or Phase III of ! Janus Particle technology has the potential to
Slide 25: Strategic Partnership: Vici Health Sciences
STRATEGIC PARTNERSHIP: VICI HEALTH SCIENCES Psycheceutical has entered into a Binding Option Agreement to acquire a controlling interest in Vici Health Sciences to assist in developing our our future IP and in-house formulations. Vici Health Sciences are U.S.-based experts in formulation and analyti
Slide 26: Corporate Objectives
CORPORATE OBJECTIVES • NeuroDirect ketamine Phase I • File FDA IND application for clinical studies to begin NeuroDirect ketamine • Reg CF/D capital raise ($15MM) Q1 Q3 ! Start Phase II clinical trial for • Finalize 2nd drug formulation NeuroDirect ketamine • Finalize 2nd drug regulatory ! License n
Slide 27: Thank You!
THANK YOU! www.psycheceutical.com | info@psycheceutical.com | OTCMKTS: BWVI
Psycheceutical Bioscience — Investor Presentation (January 2023) on 6ix